(Q52148833)

23 April 2018

title

Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436. (English)

1 reference

23 April 2018

0 references

David A Katz

1

1 reference

23 April 2018

Wei Liu

2

1 reference

23 April 2018

Charles Locke

3

1 reference

23 April 2018

Sandeep Dutta

4

1 reference

23 April 2018

Katherine A Tracy

5

1 reference

23 April 2018

publication date

26 September 2015

1 reference

23 April 2018

number of pages

11

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

23 April 2018

volume

233

1 reference

23 April 2018

issue

1

1 reference

23 April 2018

page(s)

71-81

1 reference

23 April 2018

https://scigraph.springernature.com/pub.10.1007/s00213-015-4089-5

exact match

0 references

cites work

Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

Characterization of a novel and selective V1B receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

High vs low anxiety-related behavior rats: an animal model of extremes in trait anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers and Elderly Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

A review of Atypical depression in relation to the course of depression and changes in HPA axis organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

The vasopressin Avpr1b receptor: molecular and pharmacological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

Slow wave sleep, shallow torpor and hibernation: homologous states of diminished metabolism and body temperature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

Plasma levels of arginine vasopressin elevated in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4089-5

Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26407603

12 December 2020

inferred from PubMed ID database lookup

Persistent neuroendocrine dysregulation in major depressive disorder: a marker for early relapse

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26407603

12 December 2020

inferred from PubMed ID database lookup

The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26407603

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00213-015-4089-5

1 reference

23 April 2018

release_4kqslzc4yjg2ljq3aex4dujkbe

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4kqslzc4yjg2ljq3aex4dujkbe

24 November 2022

mapped directly with Wikidata item

PubMed ID

26407603

1 reference

23 April 2018